QUESTION: Is TGTX going to report positive results that increases their stock price, when they report their upcoming Phase 3 Unity-CLL PFS readout*?
On Sept. 25, 2018, TGTX took a big hit to its credibility and its stock price, when it reported that the DSMB in the UNITY-CLL trial could NOT conduct the planned ORR analysis, and therefore, TGTX would not seek accelerated regulatory approval based on ORR. Rather, they would wait for the primary outcome PFS data. Well, according to TGTX, we should see the PFS results this quarter.
Below is the slide that TGTX's CEO likes to show when expressing his view that the trial has a high likelihood of success.
What are your thoughts?
*By responding, you are automatically entered into our Amp March 2020 Favorite Post Contest. We will select our favorite post from any of our forums on ampbioresearch.com, made between Feb 21, 2020 and Mach 31, 2020. The winner will receive a $100 Amazon gift card. Our selection will be based on the value we perceive that our readers will get from the post and the quality of diligence and understanding that goes into the post. Extra credit to anyone who tweets a link to their post or retweets our post with an ampbioresearch.com discussion link, to their Twitter followers. Assure you include @AmpBioResearch if you retweet our or your post with a link. Amp employees are not eligible.